Personalisation of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives;Personalizzazione dei contraccettivi orali. Brevi principi farmacologici e indicazioni pratiche nella prescrizione di un contraccettivo orale

Minerva Ginecologica

Volumn 59, Issue 4, 2007, Pages 415-425

  Cianci, A ^a   De Leo, V ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Contraception; Estrogens; Progestins

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG; YASMINELLE;

AMENORRHEA; BREAST DISEASE; CONTRACEPTION; DRUG FORMULATION; DRUG MECHANISM; DYSPAREUNIA; EDEMA; HUMAN; MENSTRUAL CYCLE; MENSTRUATION DISORDER; OLIGOMENORRHEA; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SPOTTING; TREATMENT OUTCOME; WATER RETENTION;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; ESTROGENS; ETHINYL ESTRADIOL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MENSTRUAL CYCLE; PATIENT SATISFACTION; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREMENSTRUAL SYNDROME; PROGESTERONE; QUALITY OF LIFE;

EID: 36349025760     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Melis GB, Lello S, Murgia C, Paoletti AM. Contraccezione estroprogestinica dopo il 2000. Roma: Il Pensiero Scientifico Editore; 2002.
2. Hannaford P. Cardiovascular events associated with different combined oral contraceptives: a review of current data. Drug Safety 2000;22:361-71.
3. rd ed. Philadelphia: WB Saunders Company; 1991.p.309-56.
4. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51.
5. Krattenmacher R. Drospirenone: pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
6. Caruso S, Agnello C, Intelisano G, Farina M, Di Mari L, Cianci A. Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene. Contraception 2004;69:237-40.
7. Oelkers W, Foridart JM, Dombrovicz M, Welter A, Heithecker R. Effect of a new oral contraceptive containing an antimineralocorticoid progestrogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21.
8. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000;5:124-34.
9. Coenen CM, Thomas CM, Borm GF, Hollanders JM, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996;53:171-6.
10. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995;51:99-110.
11. Stachenfeld NS, Silva C, Keefe DL, Kokoszka CA, Nadel ER. Effects of oral contraceptives on body fluid regulation. J Appl Physiol 1999;87:1016-25.
12. Van der Mooren MJ, Klipping C, Van Aken B, Helmerhorst E, Spielmann D, Kluft C. A comparative study of the effects of gestodene 60 μ/ ethinylestradiol 15 μg and desogestrel 150 μg/ ethinylestradiol 20 μg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care 1999;4 Suppl 2:27-35.
13. Blode H, Wuttke W, Loock W, Roll G, Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 2000;5:256-64.
14. Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr 2001;73:19-26.
15. Mansour D. Yasmin- a new oral contraceptive, a new progestogen: the reasons why. Eur J Contracept Reprod Health Care 2000;5:9-16.
16. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception 2006;73:23-9.